Last updated: September 13, 2026

Bacitracin zinc and polymyxin B sulfate are mature generic antibiotics used mainly in topical and ophthalmic ointments. The combination has no meaningful remaining market exclusivity, limited patent protection, and low manufacturer pricing power. Revenue is distributed across generic manufacturers, private-label suppliers, hospitals, pharmacies, and consumer-health channels rather than reported as a standalone branded product.

The commercial outlook is stable to declining in value. Demand remains recurring because of wound care, minor skin infections, ophthalmic infections, and post-procedure use, but generic competition, low unit prices, substitution by alternative antibiotics, and antimicrobial-stewardship policies limit growth.

What products contain bacitracin zinc and polymyxin B sulfate?

The principal U.S. combination is bacitracin zinc and polymyxin B sulfate ointment. It is marketed in two broad categories:

Product category	Active ingredients	Typical route	U.S. regulatory status	Primary customers
Ophthalmic ointment	Bacitracin zinc plus polymyxin B sulfate	Eye	Prescription generic product	Hospitals, ophthalmologists, pharmacies
Topical ointment	Bacitracin zinc plus polymyxin B sulfate	Skin	Generic and private-label products; market status varies by formulation	Retail pharmacies, hospitals, consumers
Triple-antibiotic products	Bacitracin zinc, polymyxin B sulfate, and neomycin sulfate	Skin	Primarily OTC topical products	Consumer-health and retail channels

Bacitracin is usually supplied as bacitracin zinc rather than uncomplexed bacitracin. Polymyxin B is supplied as polymyxin B sulfate. The products are generally formulated as ointments because the oily vehicle supports local retention on skin or the ocular surface.

The combination should be distinguished from neomycin-containing triple-antibiotic products such as Neosporin. Neomycin is not part of the two-ingredient bacitracin and polymyxin B formulation.

What is the FDA regulatory status of bacitracin and polymyxin B sulfate?

The ophthalmic combination is an established prescription product with generic competition. FDA labeling identifies bacitracin zinc and polymyxin B sulfate ophthalmic ointment as an antibacterial product for susceptible ocular infections and related ophthalmic indications.[1]

The topical market is more fragmented. Some products are regulated as OTC drugs under the FDA topical first-aid framework, while ophthalmic formulations generally remain prescription products. Regulatory status depends on route, concentration, labeling, manufacturing source, and the specific FDA application.

FDA regulatory characteristics

Regulatory issue	Market implication
No new molecular entity status	No NCE exclusivity remains
Generic ophthalmic approvals	Multiple suppliers can compete through ANDA pathways
OTC topical products	Retail distribution is broad, but brand differentiation is weak
Sterile ophthalmic manufacturing	Higher compliance and production barriers than nonsterile topical ointments
Drug labeling	Indications and route-specific warnings constrain promotional flexibility

FDA labeling warns about hypersensitivity, prolonged use, superinfection, and inappropriate use in nonbacterial conditions. Bacitracin and polymyxin products are not substitutes for systemic antibiotics when deeper or spreading infections are present.[1]

When does bacitracin and polymyxin B sulfate lose exclusivity?

The combination lost practical market exclusivity decades ago. Bacitracin and polymyxin B are old antibiotics, and the active ingredients do not have current product-level exclusivity that would prevent generic competition.

No meaningful remaining exclusivity period is associated with:

New chemical entity exclusivity
Orphan-drug exclusivity
Pediatric exclusivity
New clinical investigation exclusivity
A modern composition-of-matter patent
A commercially relevant formulation patent blocking ordinary generic ointments

The U.S. Orange Book framework is relevant primarily to approved prescription ophthalmic products. The FDA Orange Book does not create market exclusivity by itself; it records patent and exclusivity information submitted for approved applications.[2]

Exclusivity timeline

Period	Commercial event
1940s	Bacitracin and polymyxin antibiotics developed and introduced
Mid-20th century	Topical and ophthalmic uses become established
Late 20th century	Generic and private-label competition expands
2000s-2010s	Mature low-price market with multiple suppliers
2020s	No meaningful exclusivity barrier; supply and manufacturing determine availability

What patents protect bacitracin and polymyxin B sulfate?

The core active ingredients are not protected by enforceable U.S. composition patents. Their age places them well beyond ordinary patent terms.

Current intellectual-property value is concentrated in narrow areas rather than in the antibiotics themselves:

Specific delivery systems.
Proprietary ophthalmic vehicles.
Preservative-free or low-irritation formulations.
Packaging and dispensing systems.
Combination products with newer active ingredients.
Manufacturing processes with limited commercial relevance.
Brand trademarks and trade dress.

An ordinary bacitracin zinc and polymyxin B sulfate ointment is therefore exposed to direct generic substitution. A manufacturer cannot normally obtain durable exclusivity merely by changing tube size, excipient proportions, or packaging unless the change supports a valid patent and produces a meaningful regulatory or commercial distinction.

What formulations are protected?

Potentially protectable formulation elements include:

Improved ocular residence time.
Reduced viscosity variability.
Preservative-free packaging.
Single-dose ophthalmic delivery.
Improved stability of polymyxin B.
Reduced patient irritation.
Specialized wound-care vehicles.
Combination delivery with corticosteroids or other antimicrobials.

These features can support narrow patent claims, but they do not necessarily prevent substitution with standard generic ointment. Their commercial value depends on whether physicians, hospitals, payers, or consumers view the formulation as clinically superior.

How many patents cover bacitracin and polymyxin B sulfate?

There is no meaningful patent estate covering the two active ingredients as a conventional combination. The relevant patent count is effectively zero for broad, enforceable U.S. composition protection.

A larger number of historical or peripheral patents may appear in patent databases. Those documents can relate to:

Antibiotic production.
Fermentation methods.
Purification.
Pharmaceutical bases.
Ophthalmic delivery.
Multi-active formulations.
Packaging systems.
Non-U.S. rights.

Historical patent records should not be treated as commercial barriers unless the patent is unexpired, enforceable in the relevant jurisdiction, relevant to the marketed product, and owned or licensed by a party with a litigation strategy.

Are there Paragraph IV challenges for bacitracin and polymyxin B sulfate?

Paragraph IV litigation is not a major current market feature for this combination. Paragraph IV certifications are most commercially important when a generic applicant challenges an unexpired Orange Book patent for an approved branded product. Bacitracin zinc and polymyxin B sulfate have no widely recognized active patent barrier comparable to protected small-molecule products such as branded oncology or cardiovascular drugs.

Generic applicants can generally enter through abbreviated applications without confronting a material patent thicket. Competition is more likely to arise from:

ANDA approvals.
Manufacturer exits and reentries.
Contract-manufacturing changes.
FDA inspections.
Product discontinuations.
Hospital contracting decisions.

The principal legal risks are product liability, cGMP enforcement, labeling disputes, and supply-contract issues rather than patent infringement litigation.

What is the Orange Book status of bacitracin and polymyxin B sulfate?

The Orange Book is relevant to approved prescription ophthalmic products, but it does not create a significant exclusivity position for the combination. The commercial analysis should separate:

The approved reference product.
Generic ophthalmic ointments.
OTC topical products.
Discontinued or inactive applications.
Patents listed against a particular NDA.

An Orange Book listing, if present for a specific reference product, may relate to a narrow formulation or delivery feature. It does not automatically cover every topical or ophthalmic product containing bacitracin zinc and polymyxin B sulfate.[2]

The market has no clear evidence of a broad, live Orange Book patent blocking standard generic ointment entry.

Which companies compete in the bacitracin and polymyxin B sulfate market?

Competition is distributed among generic pharmaceutical companies, specialty ophthalmic manufacturers, contract manufacturers, and consumer-health companies. The supplier base can change when firms discontinue low-margin products or transfer manufacturing rights.

Relevant competitor categories include:

Competitor group	Competitive role
Generic prescription manufacturers	Supply ophthalmic ointments to wholesalers and pharmacies
Specialty ophthalmic companies	Focus on sterile manufacturing and ophthalmology channels
Consumer-health companies	Sell topical antibiotic products and private-label goods
Hospital suppliers	Provide institutional packs and contract products
Contract manufacturers	Produce tubes, ointments, and sterile ophthalmic products for brand owners

Retail consumer recognition is stronger for triple-antibiotic products than for the two-ingredient combination. That creates a commercial distinction: the prescription ophthalmic segment competes on availability and formulary status, while the topical segment competes on brand recognition, shelf placement, price, and retailer sourcing.

How strong is the patent estate for bacitracin and polymyxin B sulfate?

The patent estate is weak for the core product and potentially stronger for differentiated delivery systems.

Patent dimension	Strength
Active-ingredient composition	Very weak; historical compounds
Standard ointment formulation	Weak
Standard ophthalmic indication	Weak
Manufacturing process	Low to moderate, usually narrow
Preservative-free delivery	Moderate if supported by valid claims
Single-dose packaging	Moderate but easy to design around
Combination with newer actives	Product-specific
Trademark and brand recognition	More relevant than patent protection

Commercial durability depends more on manufacturing reliability, FDA compliance, distribution, and customer contracts than on intellectual property.

What manufacturing and supply barriers affect the market?

Sterile ophthalmic ointment production is the main technical barrier. Manufacturers must control:

Sterility assurance.
Particulate contamination.
Uniformity of active ingredients.
Ointment viscosity.
Tube filling.
Container-closure integrity.
Microbial limits.
Stability through labeled shelf life.

Bacitracin and polymyxin B sulfate are older ingredients, but the finished product still requires qualified API sources and validated manufacturing. A supplier with a sterile ophthalmic facility may have a stronger market position than a low-cost supplier without reliable capacity.

Supply disruptions can create temporary pricing power. That power is usually limited because competitors can replace the product when they have approved capacity and available inventory. Shortages can also accelerate hospital formulary substitution toward alternative ophthalmic antibiotics.

What is the financial trajectory for bacitracin and polymyxin B sulfate?

Drug-specific revenue is not generally reported by public companies because the product is sold within broader generic, ophthalmic, or consumer-health portfolios. Public filings usually aggregate the product with other mature pharmaceuticals.

The financial trajectory has four defining characteristics:

Low unit economics

Standard ointments are low-cost products. Gross margins can be pressured by:

API costs.
Sterile manufacturing.
Small production runs.
Packaging expenses.
Wholesaler discounts.
Retailer fees.
FDA compliance costs.

Stable underlying demand

Use remains recurring in wound care, minor skin injury, ophthalmic infections, and selected postoperative settings. Demand is less sensitive to economic cycles than discretionary consumer products.

Limited volume growth

Clinical substitution, antimicrobial stewardship, reduced use of prophylactic antibiotics, and physician preference for alternative agents constrain expansion. Mature generic products typically grow through market-share changes rather than increased underlying demand.

Periodic price spikes

Prices can rise temporarily when a supplier exits, an FDA action limits availability, or sterile manufacturing capacity is disrupted. These increases are usually unstable because competitors can reenter or expand supply.

Commercial outlook

Scenario	Market effect	Probability profile
Base case	Flat to low-single-digit decline in value; stable demand	Most likely
Supply disruption	Temporary price increase and share transfer	Recurring but episodic
New differentiated formulation	Higher price potential in a narrow niche	Limited
Broad generic entry	Lower prices and reduced supplier margins	Ongoing
Clinical displacement	Gradual volume erosion	Long-term risk

The most attractive commercial opportunities are not standard commodity tubes. They are supply-constrained sterile products, differentiated preservative-free delivery, hospital-contract products, and private-label platforms with reliable manufacturing.

What generic launch risks exist?

A new generic entrant faces low patent risk but meaningful execution risk.

Principal launch risks

FDA review delays or deficiency letters.
Facility inspection findings.
Sterility or stability failures.
Inability to secure qualified API supply.
Low reimbursement or formulary access.
Price erosion after launch.
Incumbent manufacturer price cuts.
Product liability exposure.
Small market size relative to validation costs.
Retail substitution toward triple-antibiotic brands.

A generic launch can be legally uncomplicated and still financially unattractive. The product has low switching costs, but the addressable revenue pool is also limited.

What litigation and settlement agreements affect the market?

No major active patent settlement framework defines the U.S. bacitracin zinc and polymyxin B sulfate market. The absence of a meaningful patent barrier reduces the likelihood of a commercial reverse-payment settlement comparable to those seen in high-value branded drugs.

Litigation exposure is more likely to involve:

Product contamination.
Adverse-event claims.
Manufacturing defects.
Labeling adequacy.
False advertising.
Contract disputes.
Distribution and supply agreements.

For investors and licensors, litigation diligence should focus on the manufacturer and facility rather than on a broad active-ingredient patent estate.

How does bacitracin and polymyxin B sulfate compare with competing topical antibiotics?

Product	Relative commercial position	Key advantage	Key constraint
Bacitracin plus polymyxin B	Mature two-agent product	Established use and low cost	Weak differentiation
Bacitracin alone	Commodity topical antibiotic	Simple formulation	Narrower antibacterial coverage
Triple-antibiotic ointment	Stronger consumer recognition	Broad topical familiarity	Neomycin sensitization concerns
Mupirocin	Prescription topical antibiotic	Distinct clinical positioning	Higher price and resistance concerns
Retapamulin or other newer topical agents	Niche prescription use	Differentiated mechanism or positioning	Limited volume
Ophthalmic fluoroquinolones	Broad ophthalmic use	Drops and strong physician familiarity	Resistance, pricing, and stewardship concerns

Bacitracin and polymyxin B remain viable in selected uses, but the combination does not have the pricing power or clinical differentiation of a newer prescription antibiotic.

What geographic markets are most relevant?

The United States is commercially important because it combines a large prescription market, broad retail distribution, and established generic channels. Canada and other markets may have different brand structures, OTC rules, and reimbursement dynamics.

Geographic value is influenced by:

Local OTC versus prescription classification.
National reimbursement policy.
Hospital procurement.
Availability of sterile manufacturing.
Domestic API requirements.
Import controls.
Product registration standards.
Local antimicrobial-use guidelines.

Patent risk is low across major jurisdictions because the active ingredients are old. Regulatory and manufacturing requirements remain jurisdiction-specific.

Key Takeaways

Bacitracin zinc and polymyxin B sulfate are mature antibiotic ingredients with no meaningful remaining core-product exclusivity.
The combination is sold mainly as topical and ophthalmic ointment.
The U.S. ophthalmic market is prescription and generic; topical products may be OTC or private label depending on formulation and labeling.
Standard products have weak patent protection and limited Paragraph IV exposure.
No broad live patent estate is likely to block ordinary generic entry.
Sterile ophthalmic manufacturing, facility compliance, and supply reliability are more important than patents.
Drug-specific revenue is generally not disclosed because sales are embedded in broader generic and consumer-health portfolios.
Financial value is stable but modest, with episodic pricing opportunities during shortages.
Commercial upside is concentrated in differentiated delivery, preservative-free packaging, hospital supply, and reliable manufacturing.
Long-term risks include price erosion, antimicrobial stewardship, clinical substitution, and supplier exits.

Frequently Asked Questions

Is bacitracin and polymyxin B sulfate still under patent?

No meaningful patent protection remains for the active ingredients or standard ointment combination. Narrow patents may exist for particular formulations, delivery systems, or packaging.

Is bacitracin and polymyxin B sulfate available without a prescription?

Topical products may be available OTC depending on the product and jurisdiction. Ophthalmic formulations are generally prescription products in the United States.

Does the combination have FDA exclusivity?

No meaningful current FDA exclusivity protects the conventional combination. Generic competition is established.

What is the main investment risk in this market?

The principal risks are low pricing, limited market size, sterile-manufacturing costs, supply interruptions, and product substitution rather than patent expiry.

Can a new company obtain premium pricing for this combination?

A standard ointment is unlikely to support sustained premium pricing. A preservative-free, single-dose, supply-secure, or clinically differentiated delivery system has a stronger commercial case.

References

U.S. Food and Drug Administration. (n.d.). Bacitracin zinc and polymyxin B sulfate ophthalmic ointment prescribing information. DailyMed. https://dailymed.nlm.nih.gov/
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application approvals. FDA. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda
U.S. Food and Drug Administration. (n.d.). Over-the-counter drug review and topical antimicrobial products. FDA. https://www.fda.gov/drugs/over-counter-otc-nonprescription-drugs
U.S. Food and Drug Administration. (n.d.). Drug shortages. FDA. https://www.accessdata.fda.gov/scripts/drugshortages/ 久久爱

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Clinical Trials:	1
DailyMed Link:	bacitracin; polymyxin b sulfate at DailyMed

Sponsor	Phase
Glaxo Wellcome	N/A
National Institute of Allergy and Infectious Diseases (NIAID)	N/A

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Combe	LANABIOTIC	bacitracin; polymyxin b sulfate	DISC;TOPICAL	050598-001	Sep 22, 1986		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Bacitracin; polymyxin b sulfate - Generic Drug Details

What are the generic sources for bacitracin; polymyxin b sulfate and what is the scope of patent protection?

Summary for bacitracin; polymyxin b sulfate

Recent Clinical Trials for bacitracin; polymyxin b sulfate

Anatomical Therapeutic Chemical (ATC) Classes for bacitracin; polymyxin b sulfate

US Patents and Regulatory Information for bacitracin; polymyxin b sulfate

Bacitracin and Polymyxin B Sulfate Market Dynamics, Patent Status, and Financial Outlook